Investigation of interindividual factors in cetuximab pharmacokinetics and clinical responses in Japanese head and neck cancer patients using LC-MS/MS method

Investigation of interindividual factors in cetuximab pharmacokinetics and clinical responses in Japanese head and neck cancer patients using LC-MS/MS method - Investigation of interindividual factors in cetuximab pharmacokinetics and clinical responses in Japanese head and neck cancer patients using LC-MS/MS method

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027016

Enrollment

Registered

2017-04-18

Start date

2016-06-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients treated with intravenous cetuximab for head and neck cancer 2. Patients receiving written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients discontinuing intravenous cetuximab 2. Patients who are judged by physicians as inappropriate for study enrollment

Design outcomes

Primary

Measure	Time frame
Serum concentration of cetuximab before dosing on week 4 or later	—

Countries

Japan

Contacts

Public ContactTakafumi Naito

Hamamatsu University School of Medicine Department of Hospital pharmacy

pharmacyham-adm@umin.ac.jp053-435-2763

Outcome results